DBD: Three White Soldiers detected on 26 Oct 2026

DBD is forming a three white soldiers pattern at $69.18 as the stock approaches Q3 2026 earnings scheduled for October 28. The pattern scores reflect a solid setup: structure 15.0, breakout 13.0, and volume 12.0, yielding an overall score of 78.0 with 61.88% win probability. Price trades near key resistance at $69.72, with critical support anchoring at $59.28. The measured move target sits at $72.60 (4.9% upside). Volume metrics show 207,879 shares traded at 0.9x relative volume—modest but consistent. RSI at 63.41 indicates mild momentum without overbought extremes. The setup emerges within bullish market and sector regimes (0.64 score each), validating the technical structure.

DBD's Q2 2026 results met expectations with $1.10 EPS and $927.60M revenue, with analysts projecting $5.46 EPS for fiscal 2026 and $7.30 for 2027. Consensus analyst view remains Buy with a $100 target price, and an executive purchased 700 shares in July. Wedbush reaffirmed an Outperform rating on October 17, offering increasing optimism. However, the company's financial health is in the Red zone and has been for over one month per TradeSmith. The stock has recovered 8.65% over two weeks and 10.74% over one month after a -23.76% three-month decline. This pattern forms two days before the critical earnings catalyst, creating binary risk/reward around November 28.

A successful three white soldiers breakout targets $72.60 conservatively, representing 4.9% upside from current levels with $59.28 as the invalidation point—down 14.3%. The pattern's 61.88% win probability suggests favorable odds. Volume confirmation is critical; the setup requires sustained participation above $69.72 resistance to validate breakout conviction. Historical three white soldier patterns in this technical regime typically extend 5-7% beyond the pattern high when combined with bullish market structure. Failure to breach resistance within 3-5 trading days or breakdown below $59.28 closes the trade thesis.

Q3 2026 earnings release is scheduled for October 28, two days away—an immediate binary catalyst that could negate technical setup regardless of pattern strength. DBD's financial health ranks in the Red zone, flagging fundamental concerns. Beta of 1.41 indicates 41% higher volatility than market, amplifying gap risk around earnings. The stock trades 24.87% below its 52-week high of $92.08, suggesting sellers remain overhead. Recent insider buying in July provides some support, yet the long-term three-month loss of -23.76% signals unresolved selling pressure. Volume averaging 232,220 shares daily versus current 207,879 shows participation hasn't intensified—breakout confirmation remains questionable ahead of the earnings announcement.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.